Background: During the eleven months of the novel SARS-CoV-2 disease (COVID-19) outbreak
in China and its global spread, there is a remarkable understanding of its epidemiology, pathobiology,
and clinical management strategies. While countering a heavy toll on health and the economy,
world’s regional authorities are enforcing safety guidelines and providing patient care. Currently, there
is no globally approved treatment or intervention for COVID-19.
Methods: A structured online literature search for peer-reviewed articles was conducted on PubMed,
Europe PMC, Google, WHO, CDC, FDA, and ClinicalTrials portals, using phrases such as COVID-19
treatment and intervention, COVID-19 drugs and COVID-19 vaccines.
Results: Analysis of the retrieved data showed that as a part of ‘Solidarity Clinical Trials’, hundreds of
treatment and intervention strategies, including antiviral drugs, cytokine antagonists, convalescent
plasma therapy, and vaccine candidates, have been registered worldwide. While remdesivir, the anti-
Ebola virus drug, has been approved as an ‘emergency use’ drug in the USA, favipiravir, the anti-flu
drug, has been recently approved in Russia. Tocilizumab and sarilumab, the cytokine (IL-6) antagonists,
have entered Phase-II/III clinical trials in hospitalized COVID-19 patients. Among the leading vaccine
candidates, Phase-III clinical trial results of Moderna, Pfizer and Oxford vaccines seem to be game
changers for COVID19.
Conclusion: The world health authorities have strongly and quickly responded to the COVID-19 pandemic.
Nonetheless, world bodies must unite in combating this health crisis by developing cost-effective
drugs and vaccines and making them accessible to resource-poor countries.